## EMERGENCY DEPARTMENT EVALUATION OF PATIENTS WITH POSSIBLE ACS

## **AGENDA**

## Wednesday, February 26, 2020

7:00 a.m.	BREAKFAST AVAILABLE
	Welcome to Heart House
	Athena Poppas, MD, FASE, FACC; Vice President, ACC
	Opening Remarks and Introductions
	Michael C. Kontos, MD, FACC; Co-Chair
8:00 a.m.	SESSION 1: DEFINING THE LANDSCAPE FOR TROPONIN TESTING
	Who Should Have a Troponin Measured?
	Deborah B. Diercks, MD, MSc, FACEP, FACC (10 minutes)
	Should All Hospitals Transition to hs-cTn testing?
	Cian P. McCarthy, MB, BCh, BAO (10 minutes)
	<ul> <li>Does the 99<sup>th</sup> Percentile cTn Value Mean Anything to The Clinician?</li> </ul>
	M. Odette Gore, MD, MSCS (10 minutes)
	• Interactive Table Discussion (45 minutes)
	Report Back to Full Group (30 minutes)
9:45 a.m.	BREAK
10:00 a.m.	SESSION 2: BIOMARKER BASED STRATEGIES FOR EXCLUSION OF ACUTE MI
	An International Perspective
	Martin Than, MBBS (15 minutes)
	A U.S. Perspective
	Rebecca Vigen, MD, MSCS (10 minutes)
	Role of Clinical Factors and EKG
	Simon Mahler, MD, MS, FACEP (10 minutes)
	Interactive Table Discussion (60 minutes)
	Report Back to Full Group (30 minutes)
12:05 p.m.	LUNCH
	SESSION 3: ROLE OF NONINVASIVE TESTING
1:05 p.m.	Who Should Receive Noninvasive Testing Beyond cTn?
	James K. McCord, MD, FACC (10 minutes)
	Which Test for Which Patient?
	Anna Marie Chang, MD, MSCE (10 minutes)
	What Should Be Done with the Test Results?
	Todd C. Villines, MD, FAHA, MSCCT, FACC (10 minutes)
	Shared Decision-Making: The Patient Perspective
	Eric P. Hess, MD, MSc (10 minute)
	Interactive Table Discussion (60 minutes)
	Report Back to Full Group (30 minutes)
2:1E n m	Recap of the Day and Next Steps
3:15 p.m.	James A. de Lemos, MD, FACC; Co-Chair
4:00 p.m.	ADJOURN